RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $137
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $136 to $137.
RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $136 to $137.